Steven Lichtman's Stock Ratings

Oppenheimer Analyst

Steven Lichtman is an analyst at Oppenheimer. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/05/2025

Overall Average Return

17.5%

Smart Score

Overall Average Return Percentile

76th

Number of Ratings

79

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Expert Outlook: DexCom Through The Eyes Of 11 Analysts

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst

Oppenheimer predicts growth for Penumbra Inc in MT market. Analyst initiates coverage with Outperform rating and $275 target price.

Key Takeaways From DexCom Analyst Ratings

Analyst Expectations For Medtronic's Future

What 21 Analyst Ratings Have To Say About Zimmer Biomet Holdings

Analyst Scoreboard: 7 Ratings For RxSight

Medtronic Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

Analyst Expectations For DexCom's Future

These Analysts Revise Their Forecasts On DexCom Following Q3 Results

McDonald's To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook